Wasatch Advisors Inc. increased its holdings in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) by 54.2% during the 1st quarter, HoldingsChannel reports. The firm owned 218,784 shares of the medical instruments supplier’s stock after purchasing an additional 76,921 shares during the period. Wasatch Advisors Inc.’s holdings in LeMaitre Vascular were worth $6,782,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. BlackRock Inc. lifted its stake in LeMaitre Vascular by 2.2% in the 4th quarter. BlackRock Inc. now owns 2,601,309 shares of the medical instruments supplier’s stock valued at $61,496,000 after acquiring an additional 56,161 shares in the last quarter. Conestoga Capital Advisors LLC increased its position in shares of LeMaitre Vascular by 1.5% during the 1st quarter. Conestoga Capital Advisors LLC now owns 1,698,881 shares of the medical instruments supplier’s stock worth $52,665,000 after purchasing an additional 25,750 shares during the last quarter. Vanguard Group Inc. increased its position in shares of LeMaitre Vascular by 5.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,208,742 shares of the medical instruments supplier’s stock worth $46,826,000 after purchasing an additional 66,427 shares during the last quarter. Ranger Investment Management L.P. increased its position in shares of LeMaitre Vascular by 1.3% during the 4th quarter. Ranger Investment Management L.P. now owns 732,380 shares of the medical instruments supplier’s stock worth $17,313,000 after purchasing an additional 9,688 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of LeMaitre Vascular by 1.5% during the 4th quarter. Bank of New York Mellon Corp now owns 256,990 shares of the medical instruments supplier’s stock worth $6,075,000 after purchasing an additional 3,841 shares during the last quarter. Institutional investors and hedge funds own 76.44% of the company’s stock.

Shares of LMAT stock traded up $0.01 during trading on Friday, reaching $26.25. 315 shares of the company’s stock were exchanged, compared to its average volume of 140,145. LeMaitre Vascular Inc has a twelve month low of $21.79 and a twelve month high of $38.99. The firm has a market capitalization of $514.57 million, a PE ratio of 31.43, a PEG ratio of 2.67 and a beta of 1.08.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). LeMaitre Vascular had a net margin of 20.92% and a return on equity of 16.76%. The firm had revenue of $28.48 million during the quarter, compared to analyst estimates of $27.94 million. During the same period in the prior year, the company earned $0.19 earnings per share. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. As a group, research analysts predict that LeMaitre Vascular Inc will post 0.83 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 6th. Shareholders of record on Wednesday, May 22nd will be issued a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a yield of 1.30%. The ex-dividend date of this dividend is Tuesday, May 21st. LeMaitre Vascular’s dividend payout ratio is 40.48%.

LMAT has been the topic of several recent analyst reports. ValuEngine raised LeMaitre Vascular from a “sell” rating to a “hold” rating in a research report on Friday, April 26th. Lake Street Capital boosted their target price on LeMaitre Vascular to $27.00 and gave the stock a “hold” rating in a report on Wednesday, February 20th. BidaskClub raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Roth Capital reissued a “neutral” rating on shares of LeMaitre Vascular in a report on Thursday, February 21st. Finally, Barrington Research reissued a “buy” rating and set a $32.00 target price on shares of LeMaitre Vascular in a report on Thursday, May 2nd. One analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. LeMaitre Vascular presently has an average rating of “Hold” and an average price target of $31.00.

COPYRIGHT VIOLATION WARNING: “LeMaitre Vascular Inc (LMAT) Stake Boosted by Wasatch Advisors Inc.” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/lemaitre-vascular-inc-lmat-stake-boosted-by-wasatch-advisors-inc/3021167.html.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

See Also: How to start trading in the forex market?

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.